Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2024 report and make more profitable business decisions.
Peripheral arterial disease (PAD) and peripheral vascular disease (PVD) refer to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh, or calf muscles after activity, such as walking or climbing stairs (intermittent claudication); leg numbness or weakness; coldness in lower leg or foot, especially when compared with the other side; sores on toes, feet, or legs that won’t heal; slower growth of toenails; and erectile dysfunction in men.
The Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) drugs in development market research report provide comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 50 molecules, with 49 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acclivity Technologies IncAlucent Biomedical Inc
Amplifier TX AB
AnGes Inc
Annexin Pharmaceuticals AB
AptaBio Therapeutics Inc
ARCA biopharma Inc
Athera Biotechnologies AB
Athersys Inc
Beijing Tide Pharmaceutical Co Ltd
BiogenCell Ltd
Cell Exosome Therapeutics Inc
Chengdu Shibeikang Biomedical Technology Co Ltd
Constant Therapeutics LLC
CuRAGE Therapeutics Inc
Exodos Life Sciences Limited Partnership
Foresee Pharmaceuticals Co Ltd
G&P Bioscience Co Ltd
Gurus BioPharm Inc
Helixmith Co Ltd
Hemostemix Inc
ID Pharma Co Ltd
IsomAb Ltd
JanOne Inc
LipimetiX Development Inc
MediaPharma SRL
Nangiotx Inc
Northwestern University
Novo Nordisk AS
Pharmosa Biopharm Inc
Recardio Inc
Regio Biosciences
Resverlogix Corp
Reven Holdings Inc
Rnatives Inc
Sorrento Therapeutics Inc
Symic Bio Inc
Vasa Therapeutics SP Zoo
Vascugen Inc
Venturis Therapeutics Inc
VESSL Therapeutics Ltd
Vifor Pharma Management Ltd
Zelira Therapeutics Ltd
Zhittya Genesis Medicine Inc
Table of Contents
Table
Figures
Frequently asked questions